The atezolizumab group showed a better DFS benefit than the best supportive care group among the patients with PD-L1 TC ≥50% stage II–IIIA NSCLC, with or without EGFR mutations or ALK rearrangements. This evidence concerns the gene EGFR and non-small cell lung carcinoma.